Mandate

Vinge advises Tele2 in connection with its notes issuance and tender offer

Vinge advises Tele2 AB (publ) in connection with its issuance of senior unsecured fixed rate notes in an amount of EUR 500 million and its parallel tender offer in respect of its previously issued notes due 2024.

The proceeds from the new notes, which were issued under Tele2’s EUR 5 billion EMTN-program, are applied towards the financing of the tender offer and for general corporate purposes, and the notes will be listed on the Luxembourg Stock Exchange. The notes have a tenor of six and a half years and were issued with a coupon of 3.75 per cent.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda, Ida Redander (Banking and Finance), Victor Ericsson and Emelie Svanberg (Tax)

Related

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026